natgillin/translations-raw huggingface dataset:
Your doctor or nurse should make sure you can use your pen correctly. 
Zdravnik ali medicinska sestra naj se prepričata, da znate injekcijski peresnik pravilno uporabljati.
HiSCR rate 12 weeks after re-introduction of adalimumab 40 mg weekly returned to levels similar to that observed before withdrawal (56.0 %). 
HS-II, se je po ponovni uvedbi 40 mg adalimumaba enkrat na teden raven kliničnega odziva (HiSCR) vrnila na podobno raven, kot so jo opazili pred ukinitvijo (56,0 %).
It is recommended that the patient should use a topical antiseptic wash on their HS lesions on a daily basis during treatment with Imraldi. 
Priporoča se, da med zdravljenjem z zdravilom Imraldi bolnik dnevno izpira HS lezije s topikalnim antiseptikom.
Adults with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis or axial spondyloarthritis without radiographic evidence of ankylosing spondylitis 
Odrasli z revmatoidnim artritisom, psoriatičnim artritisom, ankilozirajočim spondilitisom ali aksialnim spondiloartritisom brez radiografskega dokaza za ankilozirajoči spondilitis
Pharmacotherapeutic group: Immunosuppressants, Tumour Necrosis Factor alpha (TNF-α) inhibitors. 
Farmakoterapevtska skupina: Zdravila za zaviranje imunske odzivnosti, zaviralci tumorje-nekrotizirajočega faktorja alfa (TNF-α), oznaka ATC: L04AB04
The safety and efficacy of adalimumab were assessed in adult patients with non-infectious intermediate, posterior, and panuveitis, excluding patients with isolated anterior uveitis, in two randomised, doublemasked, placebo-controlled studies (UV I and II). 
Varnost in učinkovitost adalimumaba sta bili ocenjeni pri odraslih bolnikih z neinfekcijskim intermediarnim, posteriornim uveitisom in panuveitisom v dveh randomiziranih, dvojno slepih, s placebom kontroliranih študijah (UV I in UV II), ki nista vključevali bolnikov z izoliranim anteriornim uveitisom.
MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE 
IZDELOVALEC (IZDELOVALCI) BIOLOŠKE UČINKOVINE (UČINKOVIN) IN IZDELOVALEC (IZDELOVALCI), ODGOVOREN (ODGOVORNI) ZA SPROŠČANJE SERIJ
• If you have mild heart failure and you are being treated with Imraldi, your heart failure status must be closely monitored by your doctor. 
• Če imate blago srčno popuščanje in se zdravite z zdravilom Imraldi, mora zdravnik natančno nadzorovati stanje vašega srčnega popuščanja.
One pack contains 2 boxes, each containing 1 vial, 1 empty sterile syringe, 1 needle, 1 vial adapter and 2 alcohol pads. 
Eno pakiranje vsebuje 2 škatli, od katerih vsaka vsebuje 1 vialo, 1 sterilno injekcijsko brizgo, 1 iglo in 2 alkoholna zloženca.
Note: P = Placebo (Number at Risk); H = Adalimumab (Number at Risk). 
Opomba: P = placebo (število rizičnih preiskovancev); H = adalimumab (število rizičnih preiskovancev).
Tell your doctor if you are taking azathioprine or mercaptopurine with Imraldi. 
Povejte zdravniku, če prejemate azatioprin ali merkaptopurin sočasno z zdravilom Imraldi.
SPARCCh MRI Sacroiliac Jointsd,i 
SPARCCh MRI sakroiliakalnih sklepovd,i
Imraldi is used to treat polyarticular juvenile idiopathic arthritis and enthesitis-related arthritis. 
Zdravilo Imraldi se uporablja za zdravljenje poliartikularnega juvenilnega idiopatskega artritisa in artritisa, povezanega z entezitisom.
Upon completion of the first 104 weeks, 497 patients enrolled in an open-label extension phase in which 40 mg of adalimumab was administered every other week up to 10 years. 
Po zaključenih prvih 104 tednih so 497 bolnikov vključili v odprto nadaljevalno fazo, med katero so še do 10 let dobivali 40 mg adalimumaba vsak drugi teden.
By Week 68, patients receiving continuous adalimumab treatment showed statistically significant greater improvement of the signs and symptoms of active nr-axSpA as compared to patients allocated to treatment withdrawal during the double-blind period of the study (Table 15). 
Rezultati do 68. tedna so pokazali statistično značilno izboljšanje znakov in simptomov aktivnega nr-axSpA pri bolnikih, ki so neprekinjeno prejemali zdravilo adalimumab v primerjavi z bolniki, ki so bili v skupini za prenehanje zdravljenja v dvojno slepem obdobju študije (preglednica 15).
Imraldi is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. 
Zdravilo Imraldi je indicirano za zdravljenje aktivnega in napredujočega psoriatičnega artritisa pri odraslih, če odziv na predhodno zdravljenje z imunomodulirajočimi antirevmatiki ni bil ustrezen.
Imraldi is administered every other week via subcutaneous injection. 
Zdravilo Imraldi se odmerja vsak drugi teden v obliki subkutane injekcije.
Nail psoriasis assessments included the Modified Nail Psoriasis Severity Index (mNAPSI), the Physician's Global Assessment of Fingernail Psoriasis (PGA-F) and the Nail Psoriasis Severity Index (NAPSI) (see Table 16). 
Ocena psoriaze nohtov je vključevala prilagojeni indeks izrazitosti psoriaze nohtov (mNAPSI - Modified Nail Psoriasis Severity Index), zdravnikovo globalno oceno psoriaze nohtov (PGA-F - Physician's Global Assessment of Fingernail Psoriasis) in indeks izrazitosti psoriaze nohtov (NAPSI - Nail Psoriasis Severity Index) (glejte preglednico 16).
Always use this medicine exactly as your child's doctor or pharmacist has instructed. 
Pri uporabi tega zdravila natančno upoštevajte navodila zdravnika svojega otroka ali farmacevta.
• Use each syringe only once. 
• Vsako injekcijsko brizgo uporabite samo enkrat.
week 12 results showed statistically significant improvement of the signs and symptoms of active nr-axSpA in patients treated with adalimumab compared to placebo (Table 14). 
Rezultati po 12. tednu so pokazali statistično pomembno izboljšanje znakov in simptomov aktivnega nr-axSpA I pri bolnikih, ki so bili zdravljeni z adalimumabom, v primerjavi s placebom (preglednica 14).
JSN Score a p-value is from the pairwise comparison of methotrexate monotherapy and adalimumab/methotrexate combination therapy using the Mann-Whitney U test b p-value is from the pairwise comparison of adalimumab monotherapy and adalimumab/methotrexate combination therapy using the Mann-Whitney U test c p-value is from the pairwise comparison of adalimumab monotherapy and methotrexate monotherapy using the Mann-Whitney U test 
a Vrednost p se nanaša na parno primerjavo monoterapije z metotreksatom in kombinirane terapije z adalimumabom/metotreksatom z Mann-Whitneyevim testom U b Vrednost p se nanaša na parno primerjavo monoterapije z adalimumabom in kombinirane terapije z adalimumabom/metotreksatom z Mann-Whitneyevim testom U c Vrednost p se nanaša na parno primerjavo monoterapije z adalimumabom in monoterapije z metotreksatom z Mann-Whitneyevim testom U
The safety and efficacy of adalimumab were assessed in a multicentre, randomised, double-blind, parallelgroup study in 171 children (4-17 years old) with polyarticular JIA. 
Varnost in učinkovitost adalimumaba so ocenili v multicentrični randomizirani dvojno slepi študiji vzporednih skupin pri 171 otrocih (starih od 4 do 17 let) s poliartikularnim juvenilnim idiopatskim artritisom.
Fatty areas are easier to pinch and are good for inserting the needle correctly. 
Na območjih z več podkožne maščobe je laže zgrabiti tkivo s prsti, zato je tam laže pravilno vstaviti iglo.
If your child develops a fever that does not go away, or he/she bruises or bleeds very easily or looks very pale, call your doctor right away. 
Če vaš otrok dobi zvišano telesno temperaturo, ki ne mine, ali če se mu zlahka pojavljajo podplutbe ali zlahka zakrvavi ali je zelo bled, se takoj posvetujte z zdravnikom.
• Gently set the vial with vial adapter down on your clean work surface. 
• Previdno odložite vialo z nameščenim adapterjem na čisto delovno površino.
Patients received adalimumab 0.8 mg/kg eow (up to 40 mg), 0.4 mg/kg eow (up to 20 mg), or methotrexate 0.1 - 0.4 mg/kg weekly (up to 25 mg). 
Bolniki so prejemali adalimumab v odmerkih 0,8 mg/kg vsak drugi teden (do največ 40 mg), 0,4 mg/kg vsak drugi teden (do največ 20 mg) ali 0,1-0,4 mg/kg metotreksata na teden (do največ 25 mg).
At week 4, subjects were randomised 1:1 based on their body weight at the time to either the Low Dose or Standard Dose maintenance regimens as shown in Table 25. 
V 4. tednu so bili bolniki glede na njihovo telesno maso v tem času randomizirani v razmerju 1:1 bodisi v vzdrževalni režim z majhnim odmerkom ali vzdrževalni režim s standardnim odmerkom, kot kaže preglednica 25.
Nail psoriasis assessments included the Modified Nail Psoriasis Severity Index (mNAPSI), the Physician's Global Assessment of Fingernail Psoriasis (PGA-F) and the Nail Psoriasis Severity Index (NAPSI) (see Table 19). 
Ocena psoriaze nohtov je vključevala prilagojeni indeks izrazitosti psoriaze nohtov (mNAPSI - Modified Nail Psoriasis Severity Index), zdravnikovo globalno oceno psoriaze nohtov (PGA-F - Physician's Global Assessment of Fingernail Psoriasis) in indeks izrazitosti psoriaze nohtov (NAPSI - Nail Psoriasis Severity Index) (glejte preglednico 19).
When Imraldi therapy is initiated, a loading dose of 40 mg for patients < 30 kg or 80 mg for patients ≥ 30 kg may be administered one week prior to the start of maintenance therapy. 
Na začetku zdravljenja z zdravilom Imraldi se lahko pri bolnikih < 30 kg uporabi polnilni odmerek 40 mg in pri bolnikih ≥ 30 kg polnilni odmerek 80 mg en teden pred začetkom vzdrževalnega zdravljenja.
In the pivotal controlled trials in adults and children, 12.9 % of patients treated with adalimumab developed injection site reactions (erythema and/or itching, haemorrhage, pain or swelling), compared to 7.2 % of patients receiving placebo or active control. 
V kontroliranih preskušanjih, ki podpirajo vlogo za pridobitev dovoljenja za promet, pri odraslih in otrocih je reakcije na mestu injiciranja (eritem in/ali srbenje, krvavitve, bolečine ali oteklost) imelo 12,9 % bolnikov, ki so dobivali adalimumab, in 7,2 % bolnikov, ki so dobivali placebo ali kontrolno učinkovino.
The benefit and risk of continued long-term treatment should be periodically evaluated (see adult data in section 5.1). 
Tveganja in koristi neprekinjenega dolgotrajnega zdravljenja je treba periodično ovrednotiti (glejte podatke za odrasle bolnike v poglavju 5.1).
6 months 12 months ACR 70 
12 mesecevACR 70
Imraldi Dose for Paediatric Patients with Crohn's disease 
Odmerjanje zdravila Imraldi pri pediatričnih bolnikih s Crohnovo boleznijo
Table 21 Paediatric CD Study Discontinuation of Corticosteroids or Immunomodulators and Fistula Remission 
Študija Crohnove bolezni pri pediatričnih bolnikih Prenehanje zdravljenja s kortikosteroidi ali imunomodulatorji in remisija fistule
You should not take Imraldi with medicines containing the active substances anakinra or abatacept due to increased risk of serious infection. 
Zdravila Imraldi ne smete jemati z zdravili, ki vsebujejo učinkovini anakinro ali abatacept zaradi povečanega tveganja za resne okužbe.
Table 22 Proportion of Patientsa Achieving HiSCRb at Weeks 24 and 36 After Treatment Reassignment from Weekly Adalimumab at Week 12 Placebo (treatment withdrawal) N = 73 
b v 24. in 36. tednu po spremembi zdravljenja na jemanje adalimumaba vsak teden v 12. tednu Placebo (ukinitev zdravljenja)
Results from both studies demonstrated statistically significant reduction of the risk of treatment failure in patients treated with adalimumab versus patients receiving placebo (See Table 29). 
Rezultati iz obeh študij kažejo statistično značilno zmanjšanje tveganja za neuspeh zdravljenja pri bolnikih, ki so prejemali adalimumab, v primerjavi z bolniki, ki so prejemali placebo (glejte preglednico 29).
The recommended Imraldi induction dose regimen for adult patients with moderately to severely active Crohn's disease is 80 mg at week 0 followed by 40 mg at week 2. 
Priporočena shema odmerjanja zdravila Imraldi med indukcijo je pri odraslih bolnikih z zmerno do hudo aktivno Crohnovo boleznijo 80 mg 0. teden in nato 40 mg 2. teden.
During the controlled portions of pivotal adalimumab trials in adults of at least 12 weeks in duration in patients with moderately to severely active rheumatoid arthritis, ankylosing spondylitis, axial spondyloarthritis without radiographic evidence of AS, psoriatic arthritis, psoriasis, hidradenitis suppurativa, Crohn's disease, ulcerative colitis, and uveitis, malignancies, other than lymphoma and nonmelanoma skin cancer, were observed at a rate (95% confidence interval) of 6.8 (4.4, 10.5) per 1,000 patient-years among 5,291 adalimumab treated patients versus a rate of 6.3 (3.4, 11.8) per 1,000 patient-years among 3,444 control patients (median duration of treatment was 4.0 months for adalimumab and 3.8 months for control-treated patients). 
V kontroliranih delih preskušanj, ki podpirajo vlogo za pridobitev dovoljenja za promet adalimumaba pri odraslih, ki so trajala vsaj 12 tednov, pri bolnikih z zmerno do hudo aktivnim revmatoidnim artritisom, ankilozirajočim spondilitisom, aksialnim spondiloartritisom brez radiografskega dokaza za AS, psoriatičnim artritisom, psoriazo, Crohnovo boleznijo, ulceroznim kolitisom in uveitisom so malignome (razen limfoma in nemelanomskega kožnega raka) opažali z deležem (95-% interval zaupanja) 6,8 (4,4; 10,5) na 1.000 bolnikov-let med 5.291 bolniki, ki so dobivali adalimumab, in 6,3 (3,4; 11,8) na 1.000 bolnikov-let med 3.444 kontrolnimi bolniki (pri prvih je zdravljenje mediano trajalo 4,0 meseca in pri drugih 3,8 meseca).
Tell your doctor immediately if you get symptoms like changes in your vision, weakness in your arms or legs or numbness or tingling in any part of your body. 
Zdravniku takoj povejte, če dobite simptome, kot so spremembe vida, šibkost rok ali nog ali pa odrevenelost ali mravljinčenje v katerem koli delu telesa.
Imraldi is injected under the skin (subcutaneous use). 
Zdravilo Imraldi se injicira pod kožo (subkutana uporaba).
Serious infections, including sepsis, due to bacterial, mycobacterial, invasive fungal, parasitic, viral, or other opportunistic infections such as listeriosis, legionellosis and pneumocystis have been reported in patients receiving adalimumab. 
Pri bolnikih, ki so dobivali adalimumab, so bile opisane resne okužbe, vključno s sepso, zaradi bakterijskih, mikobakterijskih, invazivnih glivičnih, parazitskih, virusnih in drugih oportunističnih okužb, npr. listerioza, legioneloza in pnevmocistična okužba.
Hypokalaemia, uric acid increased, blood sodium abnormal, hypocalcaemia, hyperglycaemia, hypophosphatemia, dehydration 
nenormalni nivo natrija v krvi, hipokalciemija, hiperglikemija, hipofosfatemija, dehidracija
Across all treatment groups, the mean baseline PASI score was 19.7 and the baseline PGA score ranged from “mild” (<1%) to “moderate” (48%) to “severe” (46%) to “very severe” (6%). 
V vseh terapevtskih skupinah je bila povprečna izhodiščna ocena PASI 19,7, izhodiščna PGA pa je segala od "blage" (< 1 %), "zmerne" (48 %) in "hude" (46 %) do "zelo hude" (6 %).
This risk may increase if your lung function is impaired. 
Tveganje je lahko večje, če imate okvarjeno delovanje pljuč.
• DO NOT inject in an area where the skin is sore, bruised, scarred, scaly, or has red patches. 
• NE INJICIRAJTE v kožo, ki je boleča ali so na njej modrice, brazgotine, luske ali rdeče lise.
At week 12, a significantly higher proportion of patients treated with adalimumab versus placebo achieved HiSCR. 
V 12. tednu je statistično pomembno večji delež bolnikov, ki so prejemali adalimumab, dosegel klinični odziv (HiSCR) v primerjavi z bolniki, ki so prejemali placebo.
Serious infections were seen in clinical studies with concurrent use of anakinra and another TNFantagonist, etanercept, with no added clinical benefit compared to etanercept alone. 
V kliničnih študijah s sočasno uporabo anakinre in etanercepta, drugega antagonista TNF, so opazili hude okužbe brez dodatnih kliničnih prednosti v primerjavi z etanerceptom samim.
Imraldi is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. 
Zdravilo Imraldi je indicirano za zdravljenje hudega aktivnega ankilozirajočega spondilitisa pri odraslih, ki se na konvencionalno terapijo ne odzovejo ustrezno.
Very common Respiratory tract infections (including lower and upper respiratory tract infection, pneumonia, sinusitis, pharyngitis, nasopharyngitis and pneumonia herpes viral) 
zelo pogosti okužbe respiratornega trakta (vključno z okužbo spodnjega in zgornjega respiratornega trakta, pljučnico, vnetjem sinusa, vnetjem sluznice žrela, vnetjem nosnega dela žrela in pljučnim virusnim herpesom)
Fatty areas are good for inserting the needle correctly. 
Na območjih z več podkožne maščobe je laže pravilno vstaviti iglo.
If these medicines do not work well enough, patients will be given Imraldi to treat their polyarticular juvenile idiopathic arthritis or enthesitis-related arthritis. 
Če ta zdravila ne delujejo dovolj dobro, bolniki za zdravljenje poliartikularnega juvenilnega idiopatskega artritisa ali artritisa, povezanega z entezitisom, dobijo zdravilo Imraldi.
If these medicines do not work well enough, you will be given Imraldi to treat your rheumatoid arthritis. 
Če ta zdravila ne delujejo dovolj dobro, boste za zdravljenje revmatoidnega artritisa dobili zdravilo Imraldi.
If your child has been told by doctor that he/she has an intolerance to some sugars, contact your doctor before taking this medicinal product. 
Če je zdravnik vašemu otroku povedal, da ne prenaša nekaterih sladkorjev, se obrnite na zdravnika, preden bo vaš otrok vzel to zdravilo.
General handling: DO NOT dispose of any waste items until after the injection is completed. 
2) Priprava odmerka zdravila Imraldi za injiciranje Splošno ravnanje: NE ZAVRZITE nobenega uporabljenega dela, dokler ne dokončate injiciranja.
• 80 mg at week 0 and 40 mg at week 2 
• 80 mg v 0. tednu in 40 mg v 2. tednu
• Store your vial in the refrigerator, but do not freeze it. 
• Vialo shranjujte v hladilniku, vendar ne sme zamrzniti.
Table 15 Efficacy Response in Placebo-Controlled Period for Study nr-axSpA II 
Odziv učinkovitosti v s placebom kontroliranem obdobju študije nr-axSpA II Dvojno slepa
Maintenance of remission and response rates are presented in Table 24. 
Vzdrževanje remisije in deleže odziva prikazuje preglednica 24.
Week 26 Week 52 p value for Standard Dose versus Low Dose comparison 2 Immunosuppressant therapy could only be discontinued at or after week 26 at the investigator's discretion if the subject met the clinical response criterion 3 Defined as a closure of all fistulas that were draining at Baseline for at least 2 consecutive post-Baseline visits 
Zdravljenje z imunosupresivi je bilo lahko prekinjeno v 26. tednu ali po njem po raziskovalčevi diskreciji, če je bolnik izpolnjeval kriterije kliničnega odziva 3 Definiran kot zaprtje vseh fistul, ki so bile prisotne ob začetku študije na vsaj 2 zaporednih obiskih po začetku
Patients received an initial dose of 80 mg adalimumab followed by 40 mg every other week (starting one week after the initial dose) or placebo for 26 weeks followed by open-label adalimumab treatment for an additional 26 weeks. 
Bolniki so prejeli začetni odmerek 80 mg adalimumaba, ki mu je sledil 40 mg odmerek vsak drugi teden (z začetkom en teden po začetnem odmerku), ali placebo naslednjih 26 tednov, čemur je sledilo odprto zdravljenje z adalimumabom dodatnih 26 tednov.
Excipients with known effects 
Pomožne snovi z znanim učinkom:
Results from both studies demonstrated statistically significant reduction of the risk of treatment failure in patients treated with adalimumab versus patients receiving placebo (See Table 24). 
Rezultati iz obeh študij kažejo statistično značilno zmanjšanje tveganja za neuspeh zdravljenja pri bolnikih, ki so prejemali adalimumab, v primerjavi z bolniki, ki so prejemali placebo (glejte preglednico 24).
c Ankylosing Spondylitis Disease Activity Score d Partial flare is defined as ASDAS ≥ 1.3 but < 2.1 at 2 consecutive visits. 
Society b izhodišče je določeno kot izhodišče odprte faze, ko imajo bolniki aktivno bolezen c ocena bolezenske aktivnosti ankilozirajočega spondilitisa (Ankylosing Spondylitis Disease Activity Score) d Delni zagon bolezni je določen kot ASDAS ≥ 1,3 vendar < 2,1 pri dveh zaporednih obiskih.
Table 13 Efficacy Responses in Placebo-Controlled AS Study - Study I Reduction of Signs and Symptoms 
Odzivi učinkovitosti v študiji pri ankilozirajočem spondilitisu, kontrolirani s placebomštudija I Zmanjšanje znakov in simptomov
• With your free hand, pick up the needle package with the yellow syringe connector facing down. 
• S prosto roko primite pakiranje igle, in sicer tako, da rumeni konektor za brizgo gleda navzdol.
6 months 12 months ACR 50 
12 mesecevACR 50
In an open-label extension study, for patients who dose escalated from 40 mg every other week to 40 mg weekly due to a PASI response below 50 %, 26.4 % (92/349) and 37.8 % (132/349) of patients achieved PASI 75 response at week 12 and 24, respectively. 
V odprti podaljšani študiji je odziv PASI 75 v 12. tednu oziroma 24. tednu doseglo 26,4 % (92/349) oziroma 37,8 % (132/349) bolnikov, ki so jim zaradi odziva PASI pod 50 % odmerek povečali s 40 mg vsak drugi teden na 40 mg vsak teden.
If you are unsure, contact your doctor. 
Če niste gotovi, se posvetujte z zdravnikom.
In the open-label extension of RA study V, the mean change from baseline at Year 10 in the modified Total Sharp Score was 10.8, 9.2 and 3.9 in patients originally randomized to methotrexate monotherapy, adalimumab monotherapy and adalimumab/methotrexate combination therapy, respectively. 
V odprtem podaljšanju študije revmatoidnega artritisa V je bila povprečna sprememba celotne Sharpove ocene v 10. letu pri bolnikih, ki so jih na začetku randomizirali na monoterapijo z metotreksatom, monoterapijo z adalimumabom in kombinacijo adalimumaba/metotreksata, glede na izhodišče 10,8, 9,2 oz. 3,9.
• You will need a special container for waste, such as a sharps container or as instructed by your nurse, doctor or pharmacist. 
• Potrebovali boste poseben vsebnik za odpadke, kot je vsebnik za odlaganje ostrih predmetov, ali kot vam bodo naročili sestra, zdravnik ali farmacevt.
At week 4, subjects were randomised 1:1 based on their body weight at the time to either the Low Dose or Standard Dose maintenance regimens as shown in Table 19. 
V 4. tednu so bili bolniki glede na njihovo telesno maso v tem času randomizirani v razmerju 1:1 bodisi v vzdrževalni režim z majhnim odmerkom ali vzdrževalni režim s standardnim odmerkom, kot kaže preglednica 19.
Imraldi is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate. 
Zdravilo Imraldi je indicirano za zdravljenje kroničnega, neinfekcijskega, anteriornega uveitisa pri pediatričnih bolnikih, starejših od 2 let, ki se niso ustrezno odzvali ali ne prenašajo konvencionalnega zdravljenja ali pri katerih konvencionalno zdravljenje ni primerno.
In RA study V, the improvement in the HAQ disability index and the physical component of the SF 36 showed greater improvement (p <0.001) for adalimumab/methotrexate combination therapy versus methotrexate monotherapy and adalimumab monotherapy at week 52, which was maintained through week 104. 
V študiji revmatoidnega artritisa V sta se indeks invalidnosti HAQ in telesna komponenta SF 36 ob kombinirani terapiji z adalimumabom in metotreksatom po 52 tednih izboljšala bolj (p < 0,001) kot ob monoterapiji z metotreksatom ali ob monoterapiji z adalimumabom; to se je ohranilo do 104. tedna.
The recommended dose of Imraldi for patients with ankylosing spondylitis, axial spondyloarthritis without radiographic evidence of AS and for patients with psoriatic arthritis is 40 mg adalimumab administered every other week as a single dose via subcutaneous injection. 
Priporočeni odmerek zdravila Imraldi pri bolnikih z ankilozirajočim spondilitisom, aksialnim spondiloartritisom brez radiografskega dokaza za AS in pri bolnikih s psoriatičnim artritisom je 40 mg adalimumaba, apliciran v enkratni subkutani injekciji vsak drugi teden.